Skip to main content
. 2017 Jul 26;8(52):90430–90443. doi: 10.18632/oncotarget.19563

Figure 5. Kaplan-Meier progression-free survival (PFS) curves of patients with an exon 19 deletion (19DEL) vs. p.L858R mutation.

Figure 5

Patients with the 19DEL are represented by the solid (red) line and patients with the p.L858R mutation are represented by the dashed (blue) line.